Carboplatin Niosomal Nanoplatform for Potentiated Chemotherapy
Carboplatin Niosomal Nanoplatform for Potentiated Chemotherapy
复制标题
DOI：
10.1016/j.xphs.2022.06.002
复制
发表时间：
2022-10-13
影响因子：
3.8
通讯作者：
Shahmabadi, Hasan Ebrahimi
中科院分区：
文献类型：
--
作者：
Alavi, Seyed Ebrahim;Raza, Aun;Shahmabadi, Hasan Ebrahimi
本研究旨在表征稳定的纳米囊泡制剂，其可以减少卡铂（CB）的不良反应并提高其在治疗乳腺癌中的疗效。为此，使用逆相蒸发法合成CB-负载聚乙二醇（PEG）化的囊泡纳米颗粒（PEG-NS-CB）。PEG-NS-CB（226.0 × 10.6 nm）可以以受控的方式释放CB，并且与CB和CB负载的非聚乙二醇化的囊泡（NS-CB）相比，对小鼠乳腺癌4 T1细胞产生更高的细胞毒性作用（CB、NS-CB和PEG-NS-CB的IC 50分别为83.4、26.6和22.5 mM）。此外，PEG-NS-CB表现出更高的稳定性，其中其药物释放、细胞毒性和LE%的特征在制备后三个月与生产时相比没有显著变化。此外，体内实验结果表明，PEG-NS-CB引起更高的治疗作用。（存活小鼠数量：CB、NS-CB和PEG-NS-CB接受组分别为12、15和17（满分20））且毒性作用较小（CB、NS-CB和PEG-NS-CB接受组的体重分别减轻17%、12.5%和10%），与携带乳腺癌的小鼠中的NS-CB和CB相似。总体而言，本研究的结果表明，PEG-NS -CB可能是治疗乳腺癌的有前途的制剂。(C)2022年美国药学协会。爱思唯尔公司出版All rights reserved.
This study aimed to characterize a stable nano-niosome formulation, which could reduce the adverse effects of carboplatin (CB) and improve its therapeutic efficacy in the treatment of breast cancer. For this purpose, CB-loaded polyethylene glycol (PEG)ylated niosome nanoparticles (PEG-NS-CB) were synthesized using the reverse-phase evaporation method. PEG-NS-CB (226.0 10.6 nm) could release CB in a controlled manner and, compared to CB and CB-loaded non-PEGylated niosome (NS-CB), caused higher cytotoxicity effects against mouse breast cancer 4T1 cells (IC50: 83.4, 26.6, and 22.5 mM for CB, NS-CB, and PEG-NS-CB, respec-tively). Also, PEG-NS-CB demonstrated higher stability, in which its profile of drug release, cytotoxicity, and LE% did not change significantly three months after preparation compared to those at the production time. In addition, the in vivo results demonstrated that PEG-NS-CB caused higher therapeutic (the number of alive mice: 12, 15, and 17 out of 20 in CB, NS-CB, and PEG-NS-CB receiver groups, respectively) and less toxicity effects (weight loss of 17, 12.5, and 10% in CB, NS-CB, and PEG-NS-CB receiver groups, respectively), com-pared to NS-CB and CB in breast cancer-bearing mice. Overall, the results of this study suggest that PEG-NS -CB could be a promising formulation for the treatment of breast cancer. (C) 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.